Skip to main content
. 2013 Feb 11;110(9):3471–3476. doi: 10.1073/pnas.1211391110

Fig. 1.

Fig. 1.

Expression of CD11cP-I-Aβb, CD11cP-I-Aαβb and NOD.CD11cP-I-Aαβb-g7 protects 4.1-TCR transgenic and non-TCR transgenic NOD mice from diabetes. (A) DC expression of I-Aαβb or I-Aβb protected NOD mice from diabetes (n = 56 for NOD, n = 267 for NOD.CD11cP-I-Aαβb, n = 35 for NOD.CD11cP-I-Aβb). (B) DC expression of I-Aαβb-g7 protected NOD mice from diabetes (n = 56 for NOD, n = 93 for NOD.CD11cP-I-Aαβb-g7). (C) Insulitis scores of 32-wk-old NOD vs. NOD.CD11cP-I-Aβb and NOD.CD11cP-I-Aαβb-g7 females. There were no statistically significant differences between the average scores (NOD 1.92 ± 0.32 vs. NOD.CD11cP-I-Aβb 1.59 ± 0.30 vs. NOD.CD11cP-I-Aαβb-g7 1.44 ± 0.51) or percentages of islets that were insulitis-free (35 ± 9% vs. 41 ± 10% vs. 58 ± 15%). (D) DC expression of I-Aαβb or I-Aβb protected 4.1-TCR transgenic mice from diabetes (n = 25 for 4.1-NOD; n = 75 for 4.1-NOD.CD11cP-I-Aαβb; n = 15 for 4.1-NOD.CD11cP-I-Aβb). (E) DC expression of I-Aαβb-g7 protected 4.1-TCR transgenic mice from diabetes (n = 25 for 4.1-NOD; n = 24 for 4.1-NOD.CD11cP-I-Aαβb-g7). (F) Diabetes incidence of 4.1-TCR-transgenic, RAG-2−/− NOD (n = 18), NOD.K14P-I-Aβb (n = 41), NOD.CD11cP-I-Aαβb (n = 10), and NOD.CD11cP-I-Aαβb-g7 (n = 9) females. P values were calculated using Logrank test (A, B, and D–F). Statistical analysis in C was performed on averaged insulitis scores or percentages using Mann–Whitney U test.